• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Ghali on the potential of antibody-drug conjugates in variant histology bladder cancer

Video

In this video, Fed Ghali, MD, a urologic oncology fellow at the University of Washington, says that variant histology bladder cancers express Nectin-4 and Trop-2, which are cell surface targets of the FDA-approved antibody-drug conjugates, enfortumab-vedotin (Padcev) and sacituzumab govitecan (Trodelvy), respectively. Ghali presented the abstract, “Antibody-drug conjugates and variant histology muscle-invasive bladder cancer: are the targets present in primary and/or metastatic tumors?” at the 2022 AUA Annual Meeting (abstract PD53-09).

Related Videos
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Gary D. Steinberg, MD, an expert on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 2 - "Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC"
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 1 "Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC"
Related Content
© 2024 MJH Life Sciences

All rights reserved.